Shanghai Bao Pharma Co. Ltd. (2659.HK) launched its Hong Kong IPO on Tuesday, planning to sell 37.9 million shares at an offer price of HK$26.38 per share, raising up to HK$1 billion ($128 million). The stock is set to make its trading debut on Dec. 10.

Founded in 2019, Bao Pharma focuses on four key therapeutic areas, including large-volume subcutaneous drug delivery systems, antibody-mediated autoimmune disease therapies, assisted reproduction and recombinant biologics.

The company recorded revenue of 41.99 million yuan ($5.94 million) in the first half of this year, up 27.2 times year-on-year from 1.49 million yuan in the same period last year. During the same period, its loss widened 9.4% year-on-year to 180 million yuan.

According to the prospectus, the IPO has attracted several cornerstone investors, including Anke Bio Hong Kong, DC Alpha SPC, and Guotai Junan Securities Investment. That group has committed to buy HK$200.6 million worth of shares, representing about 21.77% of the total offering.

The company said IPO proceeds will be used for R&D and commercialization of its core products, advancement and registration of additional pipeline drug candidates, optimization of its technology platforms, as well as R&D of new drug candidates and for general working capital.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Muyuan is a pig breeder

Muyuan eyes global pig pen with Hong Kong IPO

The world’s largest pork producer could raise up to $1 billion in a blockbuster listing that would be one of the largest by a consumer company this year Key Takeaways:…
ATRenew is a recycler

ATRenew gears up to take its recycling act global

The company said it has begun exporting Chinese devices, and plans to build up that part of its business over the next two to three years Key Takeaways: ATRenew’s revenue…